Sanofi records win and loss with rare disease drug in Phase III trials
Sanofi’s venglustat showed a meaningful change in patients with Gaucher disease but not in patients with Fabry disease.
03 February 2026
03 February 2026
Sanofi’s venglustat showed a meaningful change in patients with Gaucher disease but not in patients with Fabry disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.